
|Articles|December 13, 2021
Current and Future Trends in Myelofibrosis: Cytopenias
This publication reviews challenges associated with the management of myelofibrosis and examines the current and future role of janus-associated kinase inhibitors in the evolving treatment landscape.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML
2
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
3
Revised Risk Stratifications Help Inform the Use of Adjuvant Cemiplimab and Neoadjuvant Strategies in Cutaneous Squamous Cell Carcinoma
4
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
5





















































































